Nasdaq:US$19.47 (+0.02) | HKEX:HK$30.95 (+0.00) | AIM:£3.13 (+0.05)
What We Do

We are an innovative, commercial-stage biopharmaceutical company based in China, striving to create differentiated novel oncology and immunology treatments with potential to be marketed globally.

Over the past 20 years, we have established a fully integrated oncology business, from discovery and development, all the way to manufacturing to commercialization.